阿比特龙治疗去势抵抗性前列腺癌安全性分析

The safety of abiraterone in the treatment of castration resistant prostate cancer

目的分析去势抵抗型前列腺癌(CRPC)患者应用阿比特龙联合泼尼松治疗早期出现不良反应(AE),分析患者部分基线值情况对不良反应出现概率的影响,并与COU-AA-302实验进行比较。方法统计分析用药12周以上的55例患者的疾病变化情况。结果不同基线值的患者出现不良反应的概率与基线值本身并无显著关联。结论阿比特龙联合泼尼松治疗CRPC,其年龄、前列腺将异性抗原(PSA)基线值、Gleason评分与患者出现AE、PSA Flare现象无明确关联,出现前列腺特异性抗原闪烁(PSA Flare)并不能说明疾病进展。

Objective To analyze the early adverse reactions of abiraterone and prednison in the treatment of patients with castration resistant prostate cancer(CRPC)and the influence of PSA baseline values on the probability of adverse reactions,and to compare with the experiment of C0U-AA-302.Methods Statistically analyzed the information of 55 patients treated over 12 weeks.Results The statistical results showed that the probability of adverse reactions in patients with different PSA baseline values was not significantly correlated with the baseline value itself.Conclusion In the treatment of CRPC with abiraterone and prednison,age,PSA baseline value and Gleason score are not clearly correlated with the probability of AE and PSA flare in patients,and the presence of PSA flare does not indicate the progress of the disease.